PerkinElmer plans to invest $100 million for its bioscience activities in India

Counted among top biosupplier companies, PerkinElmer has established direct operations in India in 2004 and currently has more than 6,000 customers and 1,700 employees in India


New Delhi: The US-based biosupplier, PerkinElmer is looking at opportunities for investing in India in the next three to five years. While the company has already invested over USD 100 million in last few years, it is mulling to invest the same amount in future.

The company’s top management in India have revealed that it will continue to invest in India in the coming years by lending support to government initiatives such as Skill India Mission and Make in India, in addition to technology innovations in the health (including science and technology), environmental screening (air, water, soil) and food quality sectors.

PerkinElmer that has three manufacturing sites in India including two in Goa and one in Uttarakhand, plans to build the capacity of local manufacturing, R&D capabilities in diagnostic and environmental screening, and skill development of young healthcare professionals in biotechnology, pharma, and life sciences.

The company has also established a service lab in Chennai that offers early biochemistry screening, cytogenetics testing, and molecular diagnostics testing.

PerkinElmer that started its operations in India during 1981, has offered instruments and services to customers in India, spanning a wide range of markets, including diagnostics, pharmaceutical, food safety, agriculture, chemical, plastics and automotive.

The company established direct operations in India in 2004 and currently has more than 6,000 customers and 1,700 employees in India. The company reported revenue of approximately USD 2.1 billion in 2016, serves customers in more than 150 countries and is a component of the S&P 500 Index.